The historical rank and industry rank for Pharmagreen Biotech's Gross Margin % or its related term are showing as below:
PHBI's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.5 * Ranked among companies with meaningful Gross Margin % only.
Pharmagreen Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Pharmagreen Biotech was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pharmagreen Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pharmagreen Biotech Gross Margin % Related Terms
Pharmagreen Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pharmagreen Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBI vs DVLP, CSTF, BLMS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmagreen Biotech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pharmagreen Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pharmagreen Biotech (PHBI) has a Gross Margin % of 0.00% as of Jun. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Gross Margin % too high?
Pharmagreen Biotech's current Gross Margin % is 0.00%.
How does Pharmagreen Biotech's Gross Margin % compare to DVLP and CSTF?
Pharmagreen Biotech's Gross Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Gross Margin % is 48.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharmagreen Biotech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmagreen Biotech's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Gross Margin % is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBI has been successfully added to your 